Bicara Therapeutics (BCAX) on Friday filed a registration statement with the US Securities and Exchange Commission to issue up to $400 million of securities.
The filing also includes a sales-agreement prospectus to sell up to $150 million of common stock under an at-the-market arrangement with TD Securities, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.